(This post drawn in part from Medgadget)
LifeBond of Israel is developing, and seeking FDA and European approval for marketing in 2010, protein-based surgical sealants that the company claims provide greater adhesive strength than blood-derived fibrin sealants. The LifeBond products, formulated in the LifeSeal SLR staple line reinforcement sealant and the LifeSeal Surgery sealant are crosslinked gelatin that are applied as an adhesive hydrogel matrix.
A key aspect to take note of in the LifeBond products is that they are protein-based and provide adhesive strength that is competitive with fibrin and other blood-based sealants. This is crucial because on blood-based sealants allow for internal use, while cyanoacrylate-based medical glues (like Ethicon’s Dermabond) provide greater adhesive strength, but are prohibited from internal use due the toxicity of cyanoacrylate and its by-products.
Excerpt from MedMarket Diligence’s Report #S175, “Worldwide Surgical Sealants, Glues and Wound Closure, 2009-2013.”:
“LifeBond was established in Israel in 2007 to develop sealants and active hemostats that incorporate a proprietary adhesive formulation that mimics the biochemical cross-linking cascade of late-stage blood coagulation. The sealant forms a network similar to the fibrin network of blood clots but has demonstrated adhesive strength the company claims is greater than that of blood-derived fibrin sealants. The LifeBond adhesive comes in gelatin-based hemostat form (LifePatch Surgery and LifePatch Heavy absorbable hemostats) and LifeSeal GI (gastrointestinal) and LifeSeal (general surgery) sealants.”
See the MedMarket Diligence report #S175, “Worldwide Surgical Sealants, Glues and Wound Closure, 2009-2013.”